This inventor holds 4 USPTO granted patents and 6 published patent applications and 6 EPO patents. Top assignees: Biophytis, Sorbonne Université, Centre National De La Recherche Scientifique. Active years: 2023-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:


Years Active: 2023-2026
Title: Pierre Dilda: Innovator in Neuromuscular and Eye Disease Treatments
Introduction
Pierre Dilda is a notable inventor based in Paris, France. He has made significant contributions to the fields of neuromuscular diseases and eye treatments. With a total of 4 patents, his work focuses on innovative solutions for serious health conditions.
Latest Patents
One of Pierre Dilda's latest patents involves phytoecdysones and their derivatives for use in the treatment of neuromuscular diseases. This patent discloses 20-hydroxyecdysone and its derivatives, which are intended for treating conditions such as spinal muscular atrophy and amyotrophic lateral sclerosis. Another significant patent pertains to chemical compounds targeting the eye, specifically derivatives of norbixin. These compounds are designed for the treatment of eye diseases, particularly age-related macular degeneration and Stargardt's disease.
Career Highlights
Throughout his career, Pierre Dilda has worked with prominent organizations such as Biophytis and Sorbonne Université. His experience in these institutions has allowed him to develop and refine his innovative ideas, contributing to advancements in medical treatments.
Collaborations
Pierre has collaborated with notable individuals in his field, including René Lafont and Mathilde Latil. These partnerships have further enhanced his research and development efforts.
Conclusion
Pierre Dilda stands out as an influential inventor whose work addresses critical health issues through innovative patents. His contributions to the treatment of neuromuscular and eye diseases reflect his commitment to improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile